Focused On-demand Library for Voltage-dependent T-type calcium channel subunit alpha-1I

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for ion channels.

 Fig. 1. The sreening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Voltage-gated calcium channel subunit alpha Cav3.3

Alternative UPACC:

Q9P0X4; B0QY12; B0QY13; B0QY14; O95504; Q5JZ88; Q7Z6S9; Q8NFX6; Q9NZC8; Q9UH15; Q9UH30; Q9ULU9; Q9UNE6


The Voltage-dependent T-type calcium channel subunit alpha-1I, also known as Voltage-gated calcium channel subunit alpha Cav3.3, plays a pivotal role in the mediation of calcium ions entry into excitable cells. It is integral to various calcium-dependent processes such as muscle contraction, hormone release, and cell division. This channel is characterized by its low-voltage activation, making it essential for pacemaking functions in neurons and cardiac cells, as well as supporting calcium signaling in secretory cells and vascular smooth muscle.

Therapeutic significance:

Given its involvement in Neurodevelopmental disorder with speech impairment and with or without seizures, understanding the role of Voltage-dependent T-type calcium channel subunit alpha-1I could open doors to potential therapeutic strategies. Targeting this protein may offer new avenues for treating conditions characterized by cognitive impairment, seizures, and developmental delays.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.